Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis

Abstract

Autoantibody status is not associated with early remission in newly diagnosed RA-patients receiving MTX. This indicates that MTX is effective as an initial treatment strategy regardless of autoantibody status.